CONVERGENCE BIO

What this means for you

Not registered yet, but its 30 May 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

98576548

Mark type

Stylized text

Filed

30 May 2024

Attorney of record

Aaron D. Hendelman

Goods and services

• Class 005 — Pharmaceuticals: pharmaceutical preparations, vaccines, medical therapeutics, and medical therapeutic pharmaceuticals for the prevention and treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations, vaccines, \ medical therapeutics, and medical therapeutic pharmaceuticals for the prevention and treatment of blood disorders, bone disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; vaccines for human use; pharmaceutical preparations, vaccines, medical therapeutics, and medical therapeutic pharmaceuticals for improving the aging nervous system, aging cardiovascular system, aging respiratory system, aging gastrointestinal system, aging reproductive system, aging renal system, aging endocrine system, aging lymphatic system, aging immune system, aging muscular system, aging skeletal system, aging integumentary system, and for boosting energy, boosting vitality, promoting sleep, alleviating anxiety, enhancing memory and cognitive ability, and weight loss; nutritional and dietary supplements for improving the aging nervous system, aging cardiovascular system, aging respiratory system, aging gastrointestinal system, aging reproductive system, aging renal system, aging endocrine system, aging lymphatic system, aging immune system, aging muscular system, aging skeletal system, aging integumentary system, and for boosting energy, boosting vitality, promoting sleep, alleviating anxiety, enhancing memory and cognitive ability, and weight loss
• Class 042 — Scientific and technological services: research and development services in the field of pharmaceutical preparations, vaccines and therapeutic drugs for the prevention and treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; research and development services of new pharmaceutical preparations, vaccines, medical therapeutics, and medical therapeutic pharmaceuticals relating to therapeutic antibodies and pharmaceuticals, and research and development of technology in the field of therapeutic antibodies, pharmaceuticals and biopharmaceuticals; research and development of new pharmaceutical preparations, vaccines, medical therapeutics, and medical therapeutic pharmaceuticals relating to therapeutic modalities for treatment of aging nervous system, aging cardiovascular system, aging respiratory system, aging gastrointestinal system, aging reproductive system, aging renal system, aging endocrine system, aging lymphatic system, aging immune system, aging muscular system, aging skeletal system, aging integumentary system, and for boosting energy, boosting vitality, promoting sleep, alleviating anxiety, enhancing memory and cognitive ability, and weight loss; development of pharmaceutical preparations, vaccines and medicines; medical research for development of therapeutic modalities for treatment of diseases; pharmaceutical, vaccine, medical therapeutic, and medical therapeutic pharmaceutical drug development and discovery; assays and reagents for use in scientific and biomedical research; clinical studies; preclinical and clinical development of therapeutic products, namely, development of medicines, pharmaceutical preparations, vaccines, medical therapeutics, and medical therapeutic pharmaceuticals

Owner

• Convergence Bio, Inc., Boston, MA, US

Prosecution history

• 27 Jan 2026 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
• 27 Jan 2026 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
• 27 Oct 2025 — NOTIFICATION OF FINAL REFUSAL EMAILED
• 27 Oct 2025 — FINAL REFUSAL E-MAILED
• 27 Oct 2025 — FINAL REFUSAL WRITTEN
• 02 Jul 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 02 Jul 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 02 Jul 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 02 Jul 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
• 02 Jul 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
• 02 Jul 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
• 05 Mar 2025 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
• 05 Mar 2025 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
• 02 Jan 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 02 Jan 2025 — NON-FINAL ACTION E-MAILED